Welcome, Guest. Please login or register.
July 16, 2019, 03:02:08 pm

Login with username, password and session length


Members
  • Total Members: 6109
  • Latest: Kchi23
Stats
  • Total Posts: 54224
  • Total Topics: 4581
  • Online Today: 71
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 43
Total: 43

Welcome

Welcome to the Hep Forums, a round-the-clock discussion area for people who have Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Core Protein Inhibitor Boosts Antiviral Activity Against Hepatitis B  (Read 405 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 618
    • Hep Mag
People who used an experimental hepatitis B virus (HBV) core protein inhibitor along with nucleoside/nucleotide analogues saw greater reductions in HBV viral load and residual HBV genetic material, which could lead to a functional cure with longer follow-up, according to a study presented at the 2019 International Liver Congress in Vienna.

The novel treatment was well tolerated, and the rapid, deep declines in HBV DNA and RNA could promote the loss of cccDNA (covalently closed circular DNA), an intermediate form that persists in the nucleus of liver cells and presents a barrier to a cure, said Jay Lalezari, MD, of Quest Clinical Research in San Francisco.

For more...
https://www.hepmag.com/article/core-protein-inhibitor-boosts-antiviral-activity-hepatitis-b

 


© 2019 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.